Discontinuation of Imatinib Therapy After Achieving a Molecular Response in Chronic Myeloid Leukemia Patients
ASH2009 -décembre 2009
Francois-Xavier Mahon, Delphine Rea, MD, PhD, Francois Guilhot, MD, Francoise Huguet, Franck Emmanuel Nicolini, MD, PhD, Laurence Legros, Aude Charbonnier, Agnes Guerci, Bruno R. Varet, MD, Gabriel Etienne, MD, Emilie Aton, Josy Reiffers, MD and Philippe Rousselot, MD, PhD
Université Victor Segalen, Bordeaux, France
Hôpital Saint Louis, Paris, France
Hôpital Jean Bernard, Poitiers, France
Dept. Hematology, Hopital de Purpan, Toulouse, France
Hematology, Hopital Edouard Herriot, Lyon, France
CHU de Nice, Nice, France
Institut Paoli Calmette, Marseille, France
CHU Brabois, Nancy, France
Hematology Dept., Paris Descartes Univ. Necker Hospital, Paris, France
Service d'Hématologie, Institut Bergonie, Bordeaux, France
Hôpital Haut Leveque - Pessac, Bordeaux, France
Université Victor Segalen Bordeaux 2, ARMA, Bordeaux, Cedex, France
Hôpital André Mignot, Versailles, France
'Conclusions - We have confirmed that CMR can be sustained after discontinuation of imatinib with a long follow-up, particularly in male patients and in pts with cytotoxic NK cells in their peripheral blood. Using stringent criteria, it is possible to stop treatment in patients with sustained CMR, even in those treated with IM as a single agent.'
http://ash.confex.com/ash/2009/webprogr ... 18033.html